Alan Bougen - Comvita Insider

CVNZF -- USA Stock  

USD 3.97  0.00  0.00%

Mr. Alan John Bougen is no longer a NonExecutive Deputy Chairman of the Board of Comvita Limited., effective October 2017. He having been a foundation Director since 1976 and serving as Managing Director until 1998. His background in the natural healthcare industry, apiculture and international marketing, brings a particularly pertinent industry and global perspective to the Board as Comvita continues in the developments of its key offshore markets. Alan is a member of the Institute of Directors and operates his own consultancy business which includes directorships in other private companies.
64 7 533 1426

Management Efficiency

The company has return on total asset (ROA) of 0.25 % which means that it generated profit of $0.25 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 6.64 % meaning that it generated $6.64 on every $100 dollars invested by stockholders.
The company has accumulated 59.79 M in total debt with debt to equity ratio (D/E) of 46.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Comvita Limited has Current Ratio of 7.87 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Comvita Limited manufactures and markets natural health products. Comvita Limited was founded in 1974 and is headquartered in Te Puke, New Zealand. Comvita operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market.Comvita Limited (CVNZF) is traded on OTC Market in USA. It is located in 23 Wilson Road South and employs 500 people.

Comvita Limited Leadership Team

Sarah Ottrey, Independent Director
Simon Pothecary, Chief Sales Officer
Ben Shaw, Chief Marketing Officer
Paul Reid, Director
Roy Ong, Chief Marketing Officer
Patrick Brus, Chief Corporate Services Officer
Alan Bougen, Non-Executive Deputy Chairman of the Board
Maurice Prendergast, Independent Director
Scott Coulter, Deputy CEO, COO
Lucas Bunt, Independent Director
Murray Denyer, Independent Director
Sharon Hollenstein, Chief Innovation Officer
Brett Hewlett, CEO
Julianne Keast, Acting CFO
Mark Sadd, Chief Commercial Officer
Thomas Cullwick, Independent Director
Neil Craig, Non-Executive Independent Chairman of the Board
Kate Selway, Acting Chief People and Culture Officer
Edward Quilty, Non-Executive Director
RalfChristian Schlothauer, Chief Technical Officer
MBA DipT, Chief Supply Chain Officer
Sarah Kennedy, Independent Director
Colin Baskin, Chief Supply Chain Officer
Julie Chadwick, Corporate Communications Manager

Stock Performance Indicators

Did you try this?

Run Portfolio Reporting Now

Portfolio Reporting

Create custom reports across your portfolios and generate quick suggestion pitch
All  Next Launch Portfolio Reporting

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Comvita and Bristol Myers Squibb. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.